The Indian biopharmaceutical sector is at a defining moment. With rapid advancements in biosimilars, cell and gene therapies, personalized medicine, digital biomanufacturing, and regulatory science, India is uniquely positioned to emerge as a global hub for innovation-driven biopharma development and manufacturing. As healthcare systems worldwide seek affordable, accessible, and cutting-edge therapies, the role of India in shaping the future of global biopharma has never been more significant.
The 6th Edition – India Biopharma Leaders Conclave 2026 aims to bring together senior leaders, policymakers, regulators, researchers, innovators, manufacturers, healthcare professionals, investors, and technology providers to discuss the opportunities, challenges, and strategic priorities that will define the industry over the next decade.
Centered around the theme “Biopharma 2030: Biosimilars, Advanced Therapies & India’s Global Leadership in Innovation and Regulation,” the conclave will serve as a platform for meaningful dialogue, knowledge exchange, and collaboration among key stakeholders shaping the future of the biopharmaceutical ecosystem.
Over two days, the conclave will explore critical topics including the evolution of biosimilars from cost-driven alternatives to innovation-led products, the readiness of India’s ecosystem for cell and gene therapies, advancements in clinical research, personalized medicine, regulatory modernization, manufacturing excellence, supply chain resilience, and the growing role of startups and academia in driving innovation.
The event will feature keynote addresses, panel discussions, industry presentations, and networking opportunities, enabling participants to gain valuable insights into emerging trends, regulatory developments, technological advancements, and best practices from across the biopharma value chain.